Charmaine Quarterman PhD - Preclinical Development / CMC (Consultant)

Charmaine has responsibility for the Company's CMC and external research and preclinical development requirements, including placing and monitoring contracts with external CROs. She is a founding director of PharMomentum Ltd, a company established in 2005 to provide research and development services to the biopharmaceutical industry. She has over 20 years experience in the development of small molecule NCEs, covering research and development as well as commercialisation. Prior to founding PharMomentum she spent 10 years in a variety of senior positions at OSI Pharmaceuticals Inc, latterly as Senior Director of Pharmaceutical Operations, and played a key role in the pharmaceutical development programme for OSI's approved anti-cancer drug Tarceva. In this role she had direct responsibility for writing and reviewing the CMC section of the Tarceva NDA (US regulatory dossier), and for establishing the supply chain to support clinical development and commercial launch of Tarceva.

Charmaine graduated in medical biochemistry in 1976, and has a PhD in therapeutics and clinical pharmacology.

John Slack PhD - Project Management (Consultant)

John Slack provides project management consultancy services to Pharminox in relation to all aspects of development. He is a founding director of PharMomentum Ltd, and is a highly experienced biopharmaceutical company executive with over fifteen years in senior corporate and development roles. From 1996 to 2005 he was VP International Development for OSI Pharmaceuticals Inc, where he had overall responsibility for the international project management of the development programme for Tarceva, an EGFR inhibitor which is now approved for the treatment of lung cancer. He was also General Manager of OSI's UK subsidiary. Prior to that he was Managing Director of Aston Molecules Ltd, a contract research and development company that John spun out of Aston University and subsequently sold to OSI.

In his earlier career John spent 16 years in academic research, primarily in the field of cancer, including 10 years as a member of the Cancer Research Campaign Experimental Chemotherapy Group based at Aston University. He graduated in pharmacy in 1973 and has a PhD in analytical chemistry.

Sue Barrowcliffe BSc - Regulatory Affairs (Consultant)

Sue is an independent drug development and regulatory affairs consultant. She has over 30 years experience in global drug development and regulatory affairs obtained in both large and small companies. Sue spent 5 years as Vice President Worldwide Product Registration at SmithKline Beecham during which time she led the marketing approval of 4 new chemical entities and multiple line extensions across a number of therapeutic areas including oncology, cardiovascular, CNS and metabolic disorders. Following this she spent 4 years at British Biotech where she led the development team in progressing a first in class antibiotic into Phase I trials and establishing Phase I and II studies for novel oncology agents. Most recently Sue spent 2 years at Chiron Biopharmaceuticals, where she led the European Regulatory Affairs team and was responsible for directing 2 successful pan- European new product registrations.

Sue has been involved with Pharminox since the beginning of 2004, initially as CEO and from October 2004 to December 2010 as a non-executive director. During her term as CEO Sue negotiated the option agreement with CRT for Phortress. Sue has a First Class Honours Degree in Biochemistry from Sheffield University.

Tracey Bradshaw PhD Pharmacology (Consultant)

Tracey has over ten years experience as a senior pharmacologist in the Experimental Cancer Chemotherapy Group based in the School of Pharmacy at the University of Nottingham. She has played a key role in the investigation and elaboration of the mechanism of action and antitumour activity of a variety of novel experimental compounds originating within this Group including aminophenylbenzothiazoles, dimethoxyphenylbenzothiazoles and heterocyclic quinols. She has published extensively in these areas.

Tracey qualified in Anatomical Studies from the University of Birmingham in 1986 and received a PhD from the University of Aston in 1990. Prior to her current appopintment, Tracey held research posts in the Department of Medical Oncology, Charing Cross Hospital London, the Department of Pharmaceutical Sciences at the University of Aston and the Department of Pharmaceutical Sciences at the University of Nottingham.

Tracey is the recipient of numerous awards for her research to date and is also a member of the Drug Discovery Committee of European Organisation for the Research and Treatment of Cancer.